ORTHOPEDIATRICS CORP

Listed Company

KIDSCIK 0001425450NasdaqAcceleratedSurgical & Medical Instruments & ApparatusFY ends Dec 31

Period

FY 2025

Revenue

$236.35M

Net Income

$-39.65M

Total Assets

$508.63M

Equity

$346.60M

Shares Out

25.68M

Op. Cash Flow

$-4.85M

KIDS$19.20−15.27% · past yearDBEQ Basic

Daily closing prices

Business

OrthoPediatrics Corp. designs, develops and markets anatomically appropriate implants, instruments and specialized braces exclusively for children with orthopedic conditions. The company offers 87 surgical and bracing systems across trauma and deformity correction, scoliosis, and sports medicine categories, as well as orthotic and prosthetic clinic services. OrthoPediatrics sells through a global network of direct sales representatives, independent sales agencies and stocking distributors across over 75 countries, with the largest revenue concentration in the United States.

Summary from 10-K filed 2026-03-04

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenue	236	205	149	122	98
Cost of revenue	64	56	37	32	25
Gross profit	173	149	111	91	73
Sales and marketing	73	64	53	46	40
General and administrative	120	103	73	58	46
Intangible asset impairment	5	2	985,000	4	0
Restructuring	6	4	0	—	—
Research and development	9	11	11	8	6
Total operating expenses	212	184	138	116	91
Operating loss	−39	−35	−27	−25	−18
Interest expense (income), net	6	3	−198,000	2	—
Loss on early extinguishment of debt	0	3	0	0	—
Fair value adjustment of contingent consideration	0	0	−3	−26	−2
Other (income) expense	−6	1	−2	2	−1
Total other (income) expenses, net	−50,000	7	−5	−22	−636,000
Net loss before income taxes	−39	−42	−21	−4	−17
Income tax expense (benefit)	460,000	−4	−338,000	−5	−1
Net loss	−40	−38	−21	1	−16
Basic (in shares)	23	23	23	21	19
Diluted (in shares)	23	23	23	21	19
Basic (in dollars per share)	−1.69	−1.64	−0.92	0.06	−0.84
Diluted (in dollars per share)	−1.69	−1.64	−0.92	0.06	−0.84

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash	20	44	31	9	8
Restricted cash	2	2	2	1	1
Short-term investments	41	25	49	109	46
Accounts receivable - trade, net of allowances of $1,501 and $1,145, respectively	54	42	35	25	18
Inventories, net	134	117	106	78	58
Prepaid expenses and other current assets	6	7	4	4	3
Total current assets	256	237	226	227	134
Property and equipment, net	50	51	41	34	29
Amortizable intangible assets, net	65	64	69	65	55
Goodwill	109	94	84	87	72
Other intangible assets	13	17	15	15	14
Other non-current assets	16	10	3	0	—
Total other assets	203	185	171	167	142
Total assets	509	473	439	428	304
Accounts payable - trade	19	9	13	11	9
Accrued compensation and benefits	14	14	11	7	5
Current portion of long-term debt with affiliate	170,000	160,000	152,000	144,000	137,000
Current portion of acquisition installment payable	2	1	10	8	13
Other current liabilities	11	10	7	5	2
Total current liabilities	46	34	42	31	30
Long-term convertible note	48	48	0	—	—
Other long-term debt, net of current portion	3	635,000	0	—	—
Acquisition installment payable, net of current portion	3	2	4	8	14
Deferred income taxes	4	3	5	6	5
Other long-term liabilities	10	6	1	492,000	293,000
Total long-term liabilities	116	85	20	18	49
Total liabilities	162	119	62	49	79
Commitments and contingencies (Note 17)	—	—	—	—	—
Common stock, $0.00025 par value; 50,000,000 shares authorized; 25,093,792 shares and 24,217,508 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	6,000	6,000	6,000	6,000	5,000
Additional paid-in capital	622	601	580	561	395
Accumulated deficit	−275	−236	−198	−177	−178
Accumulated other comprehensive loss	−523,000	−11	−6	−5	8
Total stockholders' equity	347	355	377	379	225
Total liabilities and stockholders' equity	509	473	439	428	304

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Goodwill and other intangible asset impairments	7	2	985,000	—	—
Depreciation and amortization	21	19	17	13	11
Stock-based compensation	18	14	11	7	6
Accretion of acquisition installment payable	89,000	661,000	1	—	—
Deferred income taxes	−153,000	−5	−1	−5	—
Non-cash other	244,000	90,000	0	0	—
Accounts receivable - trade	−9	−5	−10	−4	−466,000
Inventories	−8	−13	−26	−17	−5
Prepaid expenses and other current assets	414,000	−2	94,000	−506,000	−637,000
Accounts payable - trade	8	−4	1	−209,000	−567,000
Accrued expenses and other liabilities	1	537,000	7	3	1
Other	−3	315,000	−5	536,000	−584,000
Net cash used in operating activities	−5	−27	−27	−22	−13
Acquisition of Boston O&P, net of cash acquired	0	−20	0	0	0
Other acquisitions, including clinics, net of cash acquired	−16	−3	0	0	0
Acquisition of MedTech, net of cash acquired	0	0	−3	0	0
Acquisition of Rhino assets	0	0	−546,000	0	—
Sale of short-term marketable securities	0	50	113	47	9
Purchase of short-term marketable securities	−15	−25	−49	−110	0
Investment in private companies and purchases of licenses	−2	−647,000	−2	—	—
Purchases of property and equipment	−11	−14	−17	−10	−8
Net cash (used in) provided by investing activities	−44	−13	42	−113	−7
Proceeds from issuance of debt	25	74	9	—	—
Payment of debt issuance costs	0	−3	0	0	—
Proceeds from exercise of stock options	0	0	21,000	63,000	137,000
Payments on mortgage notes	−158,000	−152,000	−144,000	−137,000	—
Payment on debt	0	−12	0	—	—
Net cash provided by financing activities	24	53	7	136	6,000
Effect of exchange rate changes on cash	348,000	−175,000	633,000	619,000	−658,000
NET (DECREASE) INCREASE IN CASH AND RESTRICTED CASH	−24	13	23	1	−21
Cash paid for interest	7	3	42,000	700,000	56,000
Transfer of instruments between property and equipment and inventory	279,000	420,000	57,000	−234,000	453,000
Debt issuance costs not yet paid	0	0	127,000	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ORTHOPEDIATRICS CORP's CIK number?

ORTHOPEDIATRICS CORP's SEC CIK number is 0001425450 (1425450). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ORTHOPEDIATRICS CORP's SEC filings?

All of ORTHOPEDIATRICS CORP's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ORTHOPEDIATRICS CORP last report earnings?

ORTHOPEDIATRICS CORP (KIDS) most recently filed an earnings 8-K with the SEC on Apr 30, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001425450-26-000032). This is ORTHOPEDIATRICS CORP's most recent earnings filing of record — not a forecast of its next earnings date.

What is ORTHOPEDIATRICS CORP's most recent earnings 8-K?

ORTHOPEDIATRICS CORP's latest earnings 8-K (Item 2.02) was filed Apr 30, 2026 under accession 0001425450-26-000032. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ORTHOPEDIATRICS CORP's latest earnings 8-K →
Look up any company's CIK number →